Novartis' Late-stage Study for Spinal Muscular Atrophy Therapy Meets Primary Endpoint

USA
EnglishUK
EnglishIndia
EnglishAustralia
EnglishCanada
EnglishFrance
FrançaisSuisse
FrançaisEspaña
EspañolDeutschland
DeutschÖsterreich
DeutschSchweiz
DeutschBelgië
NederlandsNederland
NederlandsItalia
ItalianoSverige
Svenska
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
97.36 CHF | -0.46% |
|
-0.25% | +9.89% |
01:33am | NOVARTIS AG : UBS lowers his opinion and switches to Neutral | ZD |
02-12 | NOVARTIS AG : Gets a Buy rating from Deutsche Bank | ZD |